{'fraction_non_alphanumeric': 0.07324078506462423, 'fraction_numerical': 0.07563427477261848, 'mean_word_length': 4.837988826815643, 'pattern_counts': {'":': 0, '<': 3, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Hepatitis C is a predictor of acute liver injury among hospitalizations for acetaminophen overdose in the United States: A nationwide analysis

Acute liver injury (ALI) following acetaminophen overdose (AO) occurs in less than 10% of cases, but that risk is increased among alcoholics and those with chronic alcoholic liver disease. We sought to assess whether coexistent hepatitis C virus (HCV) infection potentiated the hepatotoxic effects of acetaminophen. We queried the Nationwide Inpatient Sample (1998‐2005), a 20% sample of U.S. hospitals, to identify admissions for AO using International Classification of Diseases, Ninth Revision, Clinical Modification (ICD‐9‐CM) codes. Outcomes were development of ALI (ICD‐9‐CM: 570.0, 572.2, 573.3), in‐hospital mortality, severe liver failure, and resource utilization. There were 42,781 admissions for AO in the sample, yielding a national estimate of 210,436 AO hospitalizations. HCV prevalence increased from 0.5% to 1.5% between 1998 and 2005 (P < 0.0001). The rate of ALI was 7.2%. After adjusting for confounders and excluding patients with cirrhosis, the risk of ALI increased with HCV (adjusted odds ratio [aOR] 1.80; 95% confidence interval [CI]: 1.30‐2.48), nonalcoholic fatty liver disease (aOR 7.43; 95% CI: 3.30‐16.7), alcoholic liver disease (aOR 6.46; 95% CI: 4.53‐9.21), and malnutrition (aOR 3.84; 95% CI: 2.61‐5.65). HCV was associated with greater risk of progression to severe liver failure (aOR 3.55; 95% CI: 1.88‐6.70). Crude mortality was higher in patients with HCV compared to those without HCV (2.1% versus 0.9%, P = 0.01); patients with ALI had an overall mortality of 8.6%. Length of stay was longer in patients with HCV (4.0 versus 2.6 days, P < 0.0001). Admissions with coexistent HCV also incurred two‐fold higher hospital charges than those that did not ($21,400 versus $11,400, P < 0.0001). Conclusion: Our retrospective analysis suggests that patients with HCV may be at increased risk of ALI following AO. These findings warrant further confirmation in prospective studies. (HEPATOLOGY 2008;48:1336–1341.)